{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:03Z","timestamp":1791181443660,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content>) is currently the only curative treatment for myelofibrosis (<jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>), but this option is complicated by high incidences of associated morbidity and mortality. Ruxolitinib, a janus\u2010activated kinase (<jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>) 1\/2 inhibitor, has proven to be beneficial in reduction of splenomegaly, improvement of constitutional symptoms, and possibly in overall survival. However, use of <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> inhibitors in the peritransplant period has been complicated by unpredictable response, return of <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content> symptoms or cytokine storm reaction upon discontinuation, and lack of long\u2010term response data. This review considers the current limited available data on <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> inhibitor use prior to <jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content>, including common side effects and possible impact of severe adverse events on discontinuation of the drug. We provide our experience and recommendations regarding use of <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> inhibition in patients undergoing <jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content>. Additional studies are needed to determine the optimal schedule of <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> inhibitors in the transplant protocols and their impact on engraftment, graft\u2010versus\u2010host disease, and survival.<\/jats:p>","DOI":"10.1111\/ejh.12455","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T11:13:51Z","timestamp":1411643631000},"page":"115-119","source":"Crossref","is-referenced-by-count":15,"title":["How we manage <scp>JAK<\/scp> inhibition in allogeneic transplantation for myelofibrosis"],"prefix":"10.1111","volume":"94","author":[{"given":"Tarah J.","family":"Ballinger","sequence":"first","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"},{"name":"Department of Hematology\/Oncology Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"The Elizabeth and Tony Comper MPN Program Princess Margaret Cancer Center Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroger","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation University Medical Center Hamburg Germany"},{"name":"Chronic Malignancies Working Party of EBMT EBMT study office Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Service d'Hematologie Clinique et Therapie Cellulaire H\u00f4pital Saint\u2010Antoine, AP\u2010HP Paris France"},{"name":"University Pierre &amp; Marie Curie Paris France"},{"name":"INSERM UMRs 938 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-399048"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07010.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09009.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109555"},{"key":"e_1_2_5_13_1","doi-asserted-by":"crossref","unstructured":"RobinM FrancoisS HuynhA et\u00a0al.Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis: a Preliminary Descriptive Report Of The JAK ALLO Study a Phase II Trial Sponsored By Goelams\u2010FIMIn Collaboration With The Sfgmtc 55th Annual Meeting of the American Society of Hematology ASH 2013 New Orleans USA2013.","DOI":"10.1182\/blood.V122.21.306.306"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.173"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.86"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.292"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","unstructured":"LebonD RubioM LegrandF et\u00a0al.Ruxolitinib For Patients With Primary Or Secondary Myelofibrosis before Allogeneic Hematopoietic Stem Cell Transplantation (allo\u2010HSCT): A Retrospective Study Of The Soci\u00e9t\u00e9 Fran\u00e7aise De Greffe De Moelle Et De Th\u00e9rapie Cellulaire (SFGM\u2010TC)55th Annual Meeting of the American Society of Hematology ASH 2013 New Orleans USA2013.","DOI":"10.1182\/blood.V122.21.2111.2111"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.131"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","unstructured":"SchonbergK RudolphJ CornezI BrossartP WolfD.The JAK1\/JAK2 Inhibitor Ruxolitinib Substantially Affects NK Cell Biology. 55th Annual Meeting of the American Society of Hematology ASH 2013 New Orleans USA 2013.","DOI":"10.1182\/blood.V122.21.16.16"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531103"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_2_5_25_1","unstructured":"GuptaV MesaR DeiningerM et\u00a0al.A phase I\/II open label study evaluating twice\u2010daily administration of momelotinib (GS\u20100387 CYT387) in primary myelofibrosis or post\u2010polycythemia vera or post \u2010 essential thrombocythemia myelofibrosis. 19th European Hematology Association Congress; Milano Italy June 12\u201315 2014."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12455","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:51:14Z","timestamp":1696225874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/ejh.12455"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12455","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,21]]}}}